Alcon Inc. (ALC)
NYSE: ALC · Real-Time Price · USD
74.94
-1.61 (-2.10%)
Nov 6, 2026, 4:00 PM EST - Market closed
Alcon Revenue
Alcon had revenue of $2.82B in the quarter ending June 30, 2026, with 8.74% growth. This brings the company's total for the last twelve months to $10.86B, up 8.34% year-over-year. In the year 2025, Alcon had annual revenue of $10.40B with 4.94% growth.
Revenue (ttm)
$10.86B
Revenue Growth
+8.34%
P/S Ratio
3.33
Revenue / Employee
$434,440
Employees
25,000
Market Cap
36.15B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Alcon breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.40B | 490.00M | 4.94% |
| Dec 31, 2024 | 9.91B | 456.00M | 4.82% |
| Dec 31, 2023 | 9.46B | 738.00M | 8.47% |
| Dec 31, 2022 | 8.72B | 426.00M | 5.14% |
| Dec 31, 2021 | 8.29B | 1.46B | 21.34% |
| Dec 31, 2020 | 6.83B | -675.00M | -8.99% |
| Dec 31, 2019 | 7.51B | 355.00M | 4.96% |
| Dec 31, 2018 | 7.15B | 361.00M | 5.32% |
| Dec 31, 2017 | 6.79B | 200.00M | 3.03% |
| Dec 31, 2016 | 6.59B | -161.00M | -2.38% |
| Dec 31, 2015 | 6.75B | -426.00M | -5.93% |
| Dec 31, 2010 | 7.18B | 680.00M | 10.46% |
| Dec 31, 2009 | 6.50B | 205.00M | 3.26% |
| Dec 31, 2008 | 6.29B | 695.00M | 12.41% |
| Dec 31, 2007 | 5.60B | 702.40M | 14.34% |
| Dec 31, 2006 | 4.90B | 528.10M | 12.09% |
| Dec 31, 2005 | 4.37B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Medline | 30.68B |
| Becton, Dickinson and Company | 19.46B |
| Baxter International | 11.61B |
| Solventum | 8.16B |
| Avantor | 6.64B |
| ResMed | 5.73B |
| The Cooper Companies | 4.24B |
| Align Technology | 4.16B |
ALC News
- 3 days ago - Alcon (ALC) Surges 6.8%: Is This an Indication of Further Gains? - Nasdaq
- 5 days ago - RxSight, Inc. Reports Third Quarter 2026 Financial Results - Nasdaq
- 12 days ago - Alcon price target lowered to $84 from $88 at KeyBanc - TheFly
- 19 days ago - Alcon acquires Neurotech and expands retina portfolio with ENCELTO - TheFly
- 19 days ago - Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2 - Business Wire
- 23 days ago - Alcon Secures FDA Approval For BRYTLY OTC Redness Relief Eye Drops - Nasdaq
- 23 days ago - Alcon announces FDA approval of Brytly Redness Reliever Eye Drops - TheFly
- 23 days ago - FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes - Business Wire